Showing results (71-80 of 150) with videos related to

Sort By:
Pageof 15
European Urology|December 24, 2017
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of RegimensJose Luis Perez-Gracia, Yohann Loriot, Jonathan E Rosenberg, et al.
The Journal of Urology|October 16, 2018
Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder CancerElisabeth E Fransen van de Putte, Floris Pos, Barry Doodeman, et al.
European Urology|February 1, 2015
ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant ChemotherapyFloris H Groenendijk, Jeroen de Jong, Elisabeth E Fransen van de Putte, et al.
International Journal of Cancer|August 30, 2018
Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancerT J N Hermans, C S Voskuilen, M Deelen, et al.
European Urology Oncology|February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS TrialBernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
Scientific Reports|July 19, 2017
Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder CancerK M Patel, K E van der Vos, C G Smith, et al.
Urologic Oncology|April 17, 2018
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomyBrian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
International Journal of Radiation Oncology, Biology, Physics|July 30, 2023
Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide StudyKatharina Brück, Richard P Meijer, Joost L Boormans, et al.
British Journal of Clinical Pharmacology|January 14, 2022
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapyRonald de Wit, Thomas Powles, Daniel Castellano, et al.
European Urology Focus|November 10, 2020
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract CarcinomaJens Bedke, Axel S Merseburger, Yohann Loriot, et al.
Pageof 15